5-硝基-1-苯并噻吩-2-羧酸 | 6345-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 5-硝基-1-苯并噻吩-2-羧酸
• 中文别名: 5-硝基-2-苯并噻吩羧酸；5-硝基苯并噻吩-2-羧酸
• 英文名称: 5-nitrobenzo[b]thiophene-2-carboxylic acid
• 英文别名: 5-nitrobenzothiophene-2-carboxylic acid；5-Nitro-thionaphthen-carbonsaeure-(2)；5-nitro-benzo[b]thiophen-2-carboxylic acid；5-Nitro-1-benzothiophene-2-carboxylic acid
• CAS: 6345-55-7
• 化学式: C₉H₅NO₄S
• mdl: MFCD01159700
• 分子量: 223.209
• InChiKey: ZGSMHACHDULBBY-UHFFFAOYSA-N

物化性质

• 熔点：
  239-241°C
• 沸点：
  473.6±25.0 °C(Predicted)
• 密度：
  1.624±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	5-Nitro-1-benzothiophene-2-carboxylic acid, 97% Material Safety Data Sheet
Synonym:
CAS:	6345-55-7

Section 1 - Chemical Product MSDS Name: 5-Nitro-1-benzothiophene-2-carboxylic acid, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6345-55-7	5-Nitro-1-benzothiophene-2-carboxylic	97%	unlisted

+++++
Hazard Symbols: XI

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 6345-55-7: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 238 - 241 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H5NO4S
Molecular Weight: 223.21

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 6345-55-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Nitro-1-benzothiophene-2-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 6345-55-7: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 6345-55-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 6345-55-7 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 5/12/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-硝基-1-苯并噻吩-2-羧酸 在 ammonium hydroxide 、 氯仿 、 硫酸 、 溴 、 硝酸 、 lead(II) oxide 、 iron(II) sulfate 、 溶剂黄146 、 sodium nitrite 作用下， 生成 6-bromo-benzo[b]thiophene-4,5-quinone
  参考文献：
  名称：

  Fries et al., Justus Liebigs Annalen der Chemie, 1937, vol. 527, p. 83,101

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-5-硝基苯甲醛 在 potassium carbonate 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 5-硝基-1-苯并噻吩-2-羧酸
  参考文献：
  名称：

  新型苯并[b]噻吩-二芳基脲衍生物作为潜在抗癌药的设计，合成及生物学评价

  摘要：

  一种杂种药效团方法被用于设计和合成一系列具有潜在抗癌作用的苯并[b]噻吩-二芳基脲衍生物17a-g。评估了所有目标化合物对HT-29和A549癌细胞的体外抗增殖活性。三种化合物17b，17d和17f在两种细胞系中均显示出与阳性参考药物索拉非尼相当的抗增殖活性。值得注意的是，化合物17d的IC 50活性最高在HT-29和A549细胞上的分别值为5.91和14.64μM。基于DAPI染色和碘化丙啶（PI）染色，然后流式细胞仪分析，它还诱导HT-29细胞的G0 / G1期凋亡和细胞周期停滞。分子对接研究表明17d可以很好地结合VEGFR2受体的活性位点。总的来说，化合物17d可以被认为是有前途的支架，适合进一步优化开发新的抗癌剂。

  DOI：

  10.1007/s00044-020-02559-8

文献信息

• Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins
  申请人：——

  公开号：US20040204417A1

  公开（公告）日：2004-10-14

  The invention concerns compounds of general formula (1), wherein, in particular; W represents H, SO 2 R 5 . CO(CH 2 ) n R 5 , (CH 2 ) n R 6 , CS(CH 2 ) n R 5 ; X represents S or NH; Y represents (CH 2 ) p , CO, (CH 2 ) p CO, CH═CH—CO; Z represents a hetcrocycle, imidazole, benzimidazole, isoxazole, tetrazole, oxadiazole, thiadazole, pyridine, quinazoline, quinoxaline, quinoline, thiophene; R 1 represents COOR 6 , CONR 6 R 7 , CO—NH—CH(R 6 )—COOR 7 , CH 2 NR 6 R 7 , CH 2 OR 6 , (CH 2 ) p R 6 , CH═CHR 6 ; R 2 represents in particular hydrogen, C 1 -C 10 alkyl, a substituted or unsubstituted phenyl; R 5 and R 6 represents hydrogen, C 1 —C 6 alkyl; R 5 represents a substituted or unsubstituted phenyl or naphthyl; R 6 and R 7 , identical or different, represent hydrogen, C 1 —C 15 alkyl, a hetcrocycle. an aryl; n represents 0 to 10; p represents 1 to 6. 1

  该发明涉及一般式（1）的化合物，其中，特别是；W代表H，SO2R5.CO(CH2)nR5，(CH2)nR6，CS(CH2)nR5；X代表S或NH；Y代表(CH2)p，CO，(CH2)pCO，CH═CH—CO；Z代表杂环，咪唑，苯并咪唑，异噁唑，四唑，噁二唑，硫唑，吡啶，喹唑啉，喹喔啉，喹啉，噻吩；R1代表COOR6，CONR6R7，CO—NH—CH(R6)—COOR7，CH2NR6R7，CH2OR6，(CH2)pR6，CH═CHR6；R2特指氢，C1-C10烷基，取代或未取代苯基；R5和R6代表氢，C1—C6烷基；R5代表取代或未取代苯基或萘基；R6和R7，相同或不同，代表氢，C1—C15烷基，杂环，芳基；n表示0到10；p表示1到6。
• Benzothiophene derivatives and corresponding use and composition
  申请人：Vita-Invest, SA

  公开号：US06262056B1

  公开（公告）日：2001-07-17

  Benzothiophene derivative compounds and corresponding use and composition; the compounds respond to formula (I): where Z is: —CO—, —CH(OR6)—, —C(NOR7)—; R1 is: H, C1-C6 alkyl, halogen, or —OR8; R2 and R3 are: H, alkyl, halogen, —OR8, nitro, cyano, NR9R10; —COR8; CO2R8; —SO2NR9R10; —SO2R8; —SR8; —CONR9R10; R4 and R5 are: H, alkyl, halogen, haloalkyl, —OR8, nitro, NR9R10; —COR8; CO2R8; —SO2NR9R10; —SO2R8; SR8, cyano; —CONR9R10 or R4 and R5 form a benzene ring; R6 is: H, alkyl, CO2R8, —C(O)NR9R10, naphthyl or phenyl; R7 is: H or alkyl; R8 is H, C1-C6 alkyl or phenyl; R9 and R10 are: H, alkyl or phenyl or R9 and R10 form a 5- or 6-membered ring. These compounds are effective for the treatment of anxiety or depression.

  苯并噻吩衍生物化合物及其对应的用途和组合物；这些化合物符合以下式（I）： 其中 Z 为：—CO—，—CH(OR6)—，—C(NOR7)—；R1 为：H，C1-C6 烷基，卤素，或—OR8；R2 和 R3 为：H，烷基，卤素，—OR8，硝基，氰基，NR9R10；—COR8；CO2R8；—SO2NR9R10；—SO2R8；—SR8；—CONR9R10；R4 和 R5 为：H，烷基，卤素，卤代烷基，—OR8，硝基，NR9R10；—COR8；CO2R8；—SO2NR9R10；—SO2R8；SR8，氰基；—CONR9R10 或 R4 和 R5 形成苯环；R6 为：H，烷基，CO2R8，—C(O)NR9R10，萘基或苯基；R7 为：H 或烷基；R8 为 H，C1-C6 烷基或苯基；R9 和 R10 为：H，烷基或苯基，或 R9 和 R10 形成 5 或 6 个成员的环。这些化合物对于焦虑或抑郁症的治疗是有效的。
• CNS affecting 5-oxy-3-aminomethyl-dihydro-benzofurans and benzothiophenes
  申请人：H. Lundbeck A/S

  公开号：US04847254A1

  公开（公告）日：1989-07-11

  The present invention relates to 3-aminomethyl derivatives of indane, dihydrobenzofurane, dihydrobenzothiophene, and indoline, acid addition salts thereof, isomers thereof, methods of preparation, pharmaceutical compositions and method of treating CNS-disorders such as schizophrenia, Parkinson's disease, depression, anxiety, migraine and senile dementia, or in the cure of cardiovascular diseases, by administering such a derivative.

  本发明涉及吲烷、二氢苯并呋喃、二氢苯并噻吩和吲哚啉的3-氨基甲基衍生物，其酸加成盐、异构体、制备方法、药物组合物以及通过施用此类衍生物治疗中枢神经系统疾病如精神分裂症、帕金森病、抑郁症、焦虑症、偏头痛和老年痴呆症，或在治疗心血管疾病中的方法。
• [EN] HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION
  申请人：C & C RES LAB

  公开号：WO2014196793A1

  公开（公告）日：2014-12-11

  A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.

  由式(I)表示的杂环衍生物，或其药用可接受的盐或立体异构体，对STAT3蛋白激活具有抑制作用，并可用于预防或治疗与STAT3蛋白激活相关的疾病。
• [EN] HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME<br/>[FR] COMPOSÉS HÉTÉROARYLE EN TANT QU'INHIBITEURS DE LA VOIE DE NÉCROSE PROGRAMMÉE, COMPOSITION ET PROCÉDÉ FAISANT APPEL À CEUX-CI
  申请人：ZHANG XIAOHU

  公开号：WO2021138694A1

  公开（公告）日：2021-07-08

  The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the programmed necrosis pathway.

  本公开提供了式（I）的杂环芳基化合物，其制备方法，含有它们的药物组合物，以及它们在治疗由程序性坏死途径引起或相关的疾病和紊乱中的应用。